Cargando…

Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system

Doxorubicin (DOX) is an anthracycline widely used for the treatment of solid and hematological tumors. The aim of this study was to assess the adverse event profiles of conventional DOX and liposomal DOX. This is the first study to evaluate the effect of a liposomal formulation of DOX using spontane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukuda, Akiho, Tahara, Kohei, Hane, Yuuki, Matsui, Toshinobu, Sasaoka, Sayaka, Hatahira, Haruna, Motooka, Yumi, Hasegawa, Shiori, Naganuma, Misa, Abe, Junko, Nakao, Satoshi, Takeuchi, Hirofumi, Nakamura, Mitsuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617225/ https://www.ncbi.nlm.nih.gov/pubmed/28953936 http://dx.doi.org/10.1371/journal.pone.0185654

Ejemplares similares

Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database
por: Hasegawa, Shiori, et al.
Publicado: (2017)

Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events
por: Sasaoka, Sayaka, et al.
Publicado: (2016)

Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004−2016
por: Motooka, Yumi, et al.
Publicado: (2018)

Age-related trends in injection site reaction incidence induced by the tumor necrosis factor-α (TNF-α) inhibitors etanercept and adalimumab: the Food and Drug Administration adverse event reporting system, 2004-2015
por: Matsui, Toshinobu, et al.
Publicado: (2017)

Analysis of fall-related adverse events among older adults using the Japanese Adverse Drug Event Report (JADER) database
por: Hatahira, Haruna, et al.
Publicado: (2018)

Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System
por: Naganuma, Misa, et al.
Publicado: (2019)

Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database
por: Naganuma, Misa, et al.
Publicado: (2018)

Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases
por: Hatahira, Haruna, et al.
Publicado: (2017)

Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015
por: Horibe, Megumi, et al.
Publicado: (2018)

Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database
por: Abe, Junko, et al.
Publicado: (2016)

Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database
por: Abe, Junko, et al.
Publicado: (2017)

Analysis of the time-to-onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events
por: Nakamura, Mitsuhiro, et al.
Publicado: (2015)

Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database
por: Shimada, Kazuyo, et al.
Publicado: (2019)

Analysis of drug-induced interstitial lung disease using the Japanese Adverse Drug Event Report database
por: Matsumoto, Kiyoka, et al.
Publicado: (2020)

Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
por: Sonawane, Kalyani B., et al.
Publicado: (2018)

Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age
por: ABE, Junko, et al.
Publicado: (2015)

Assessing taxane-associated adverse events using the FDA adverse event reporting system database
por: Lao, Dong-Hui, et al.
Publicado: (2021)

Cardiac adverse events associated with quetiapine: Disproportionality analysis of FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS)
por: Zou, Shu-peng, et al.
Publicado: (2023)

Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports
por: Kato, Yamato, et al.
Publicado: (2015)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Ovary and uterus related adverse events associated with statin use: an analysis of the FDA Adverse Event Reporting System
por: Jiao, Xue-feng, et al.
Publicado: (2020)

Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
por: Ding, Lingqing, et al.
Publicado: (2022)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database
por: Hasegawa, Shiori, et al.
Publicado: (2020)

Statin-Associated Muscular and Renal Adverse Events: Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System
por: Fadini, Gian Paolo, et al.
Publicado: (2018)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

Combining Social Media and FDA Adverse Event Reporting System to Detect Adverse Drug Reactions
por: Li, Ying, et al.
Publicado: (2020)

Evaluation of antibiotic-induced taste and smell disorders using the FDA adverse event reporting system database
por: Kan, Yusuke, et al.
Publicado: (2021)

Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system
por: Huang, Jing, et al.
Publicado: (2020)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Data Mining of the Public Version of the FDA Adverse Event Reporting System
por: Sakaeda, Toshiyuki, et al.
Publicado: (2013)

Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews
por: Han, Nayoung, et al.
Publicado: (2020)

Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database
por: Meng, Long, et al.
Publicado: (2021)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System
por: Raschi, Emanuel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d0ohgmkq29s89fpv5esagnkp22